Oncology Letters最新文献

{"title":"Painless perianal mucinous adenocarcinoma: A case report and literature review.","authors":"Jianping Shi, Xiaoying Wang, Junjie Yang, Guofeng Li, Yanjie Zhang","doi":"10.3892/ol.2026.15542","DOIUrl":"10.3892/ol.2026.15542","url":null,"abstract":"<p><p>Painless perianal mucinous adenocarcinoma (PMA) is characterized as a rare malignant tumor of the anal canal and rectum; its incidence rate is extremely low, and it has atypical clinical manifestations. In the present case report, a 79-year old male patient is described who presented with a painless perianal mass that had been present for 15 days. Perianal B-ultrasound examinations revealed a well-circumscribed hypoechoic mass with a maximum diameter of 3.31 cm. A pathological examination of the resected tumor specimen revealed that the tumor exhibited an expansive nodular growth pattern, accompanied by irregular infiltration of glandular structures and extensive secretion of extracellular mucus. The columnar and goblet cells presented with low-grade intraepithelial neoplasia. Immunohistochemistry examinations showed positive staining for cytokeratin (CK) 7, CK20, caudal type homeobox 2 and mucin 2. The molecular test results suggested a KRAS p. G12d activating mutation. The pathological diagnosis was PMA. The patient underwent radical local wide resection 1 month later, and no recurrence or metastasis was observed during a follow-up period of 12 months. The present case report provides a real-world reference for the clinical diagnosis, selection of treatment plans and evaluation of the prognosis of painless PMA.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 5","pages":"187"},"PeriodicalIF":2.2,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methylglyoxal-derived glycated albumin enhances the stemness potential of invasive ductal carcinoma-derived breast cancer stem-like cell line KAIMRC1.","authors":"Maram Aldawood, Mariam K Alamoudi, Abdulmonem A Alsaleh, Nouf Alharbi, Sarah Huwaizi, Rehab Alroshody, Rizwan Ali, Rafa Almeer, Sabine Matou-Nasri","doi":"10.3892/ol.2026.15541","DOIUrl":"10.3892/ol.2026.15541","url":null,"abstract":"<p><p>Type 2 diabetes mellitus (T2DM) is a risk factor for breast cancer (BC) development and recurrence due to multifactorial mechanisms, including the generation of glycated proteins under hyperglycemic conditions. Emerging evidence indicates that hyperglycemia promotes the formation and expansion of BC stem-like cells (BCSC), contributing to worse outcomes in patients with T2DM. To support early detection and personalized therapy, there is an urgent need to identify novel biomarkers that specifically target BCSCs in patients with T2DM. The present study examined the effects of glycated albumin (GA) on the cellular functions of KAIMRC1, a naturally immortalized BCSC line derived from invasive ductal carcinoma (IDC), the primary breast carcinoma developed in patients with T2DM. Cells were subjected to <i>in vitro</i> assays, including soft agar colony formation, real-time monitoring of cell proliferation, motility and invasion through a reconstituted basement membrane using the xCELLigence system and western blotting. A triple-negative BC cell line was used as a comparator. Aldehyde dehydrogenase (ALDH) activity was quantified using a biochemical assay. As expected, KAIMRC1 cells exhibited high ALDH activity, a characteristic feature of cancer stem-like cells (CSCs). GA induced dose-dependent increases in KAIMRC1 cell proliferation, motility, invasion and colony formation and was associated with elevated levels of the oncoprotein phosphorylated-ERK1/2, the receptor for advanced glycation end products (RAGE) and the stemness-associated proteins OCT3/4 and vimentin. GA-treated KAIMRC1 cells showed notable invasive capacity despite slow proliferation, consistent with known metastatic potential of quiescent CSCs. Conversely, unglycated albumin had no detectable biological effects except for an anti-mitogenic response at high concentration. Bioinformatics analyses showed that vimentin mRNA was upregulated in patients with BC and DM and was associated with a poor prognosis in patients with BC. RAGE neutralization attenuated GA-induced vimentin upregulation. Altogether, these findings show that GA exerts pro-tumorigenic effects in IDC-derived CSCs and upregulates vimentin protein expression via RAGE, highlighting the GA-RAGE axis as a potential therapeutic target and supporting vimentin as a promising prognostic marker for invasive BC in patients with DM.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 5","pages":"186"},"PeriodicalIF":2.2,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034109/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593462","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Proteomic and immunocytochemical analyses of squamous components in two- and three-dimensional-cultured pancreatic ductal adenocarcinoma cell lines.","authors":"Yuuki Shichi, Hiroki Tsumoto, Masakazu Fujiwara, Keisuke Nonaka, Yasuko Hasegawa, Seiichi Shinji, Hirofumi Rokutan, Kimimasa Takahashi, Tomio Arai, Yuri Miura, Toshiyuki Ishiwata","doi":"10.3892/ol.2026.15540","DOIUrl":"10.3892/ol.2026.15540","url":null,"abstract":"<p><p>Adenosquamous carcinoma of the pancreas consists of both adenocarcinoma and squamous cell carcinoma components and shows a worse prognosis compared with pancreatic ductal adenocarcinoma (PDAC). Given that squamous cells are absent in healthy pancreatic tissue, their origin in pancreatic tumors remains unclear. The present study aimed to analyze ductal and squamous marker expression in PDAC cell lines under two-dimensional (2D) and three-dimensional (3D) culture conditions. A total of eight PDAC cell lines were examined using liquid chromatography-tandem mass spectrometry-based proteomics and immunocytochemistry to evaluate the expression of cytokeratins (CK7, CK20 and CK5/6), p63 and p40. CK7 was found to be expressed under both culture conditions in epithelial-type PDAC cell lines but not in mesenchymal-type PDAC cell lines. CK20 was not detected in any PDAC cell line under either culture condition. Among the squamous cell markers, CK5/6 was expressed in PK-59, PK-1 and T3M-4 cells in 2D culture, but not in PK-59 cells in 3D culture. Furthermore, p63 and its isoform p40 were strongly expressed in PK-8, PK-1 and T3M-4 cells in 2D culture but were not expressed in PK-8 cells in 3D culture. These squamous cell markers were not observed in mesenchymal PDAC cell lines, except for p63 in MIA PaCa-2 cells. Epithelial PDAC cells maintained their CK7⁺/CK20^- adenocarcinoma characteristics, while a number of cell lines also acquired squamous features. Overall, the present study provides new insight into the squamous cell component of PDAC and may therefore contribute to understanding the mechanism of its formation.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 5","pages":"185"},"PeriodicalIF":2.2,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034107/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic reprogramming-a breakthrough point in overcoming resistance to BRAF mutant melanoma targeted therapy (Review).","authors":"Xueting Zhao, Fang Chen, Huibin Li","doi":"10.3892/ol.2026.15539","DOIUrl":"10.3892/ol.2026.15539","url":null,"abstract":"<p><p>Targeted therapy for BRAF-mutant melanoma induces metabolic reprogramming, which drives the development of drug resistance. Studies indicate that following treatment with BRAF inhibitors and/or MEK inhibitors, melanoma cells alter metabolic pathways by modifying various regulatory factors. These adaptations include increased lactate accumulation, enhanced oxidative phosphorylation, elevated glutamine utilization via the tricarboxylic acid cycle, activation of the kynurenine pathway and increased fatty acid synthesis. Collectively, these alterations reshape the tumor microenvironment, suppress ferroptosis and activate alternative signaling pathways, thereby conferring resistance to targeted therapy. This paper systematically reviews the mechanisms underlying therapy-induced metabolic reprogramming in BRAF-mutant melanoma and explores potential combinatorial strategies that target these metabolic vulnerabilities alongside established melanoma therapies. Key metabolic targets with promising therapeutic potential identified include lysine-specific demethylase 1, oxidative phosphorylation components, phosphoglycerate dehydrogenase, indoleamine 2,3-dioxygenase 1 and lipid metabolism enzymes such as fatty acid synthase and 3-hydroxy-3-methylglutaryl-coenzyme a reductase.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 5","pages":"184"},"PeriodicalIF":2.2,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive performance of image processing techniques in the diagnosis of bone metastasis: A meta-analysis of a confusion matrix.","authors":"Yupeng Hu, Wen Liao, Ying Er, Qifeng Tao","doi":"10.3892/ol.2026.15537","DOIUrl":"10.3892/ol.2026.15537","url":null,"abstract":"<p><p>Bone metastasis, a common cause of disability, markedly affects prognosis and life expectancy, and is usually diagnosed through radiographic imaging. An early and accurate diagnosis of bone metastasis is critical in order to optimize therapeutic strategies and palliative care. Computer-based image processing techniques have proved promising to improve diagnostic efficiency. The present systematic review and meta-analysis aimed to evaluate the efficacy of the diagnostic performance metrics of computational image processing techniques in patients with lung cancer and bone metastasis. Following the Preferred Reporting Items for Systematic reviews and Meta-analysis guidelines, a comprehensive literature search was conducted across different databases between January 2010 and December 2024. Studies assessing computational image-processing techniques in patients with lung cancer and bone metastasis were included. Confusion matrix parameters were extracted and the bivariate Reitsma model was applied to estimate the pooled diagnostic performance. Heterogeneity and inconsistency (variance of components and I² values), and risk of bias (quality assessment of diagnostic accuracy studies-2 tool) were appraised for the included studies. Overall, 6 studies were included in the meta-analysis. A high overall diagnostic accuracy (area under the summary receiver operating characteristic curve, 0.931), a pooled sensitivity of 0.86 and a specificity of 0.88 were achieved. Favorable positive and negative likelihood ratios (7.22 and 0.165, respectively) indicated the strong discriminatory ability of the model. Despite some heterogeneity, stable high negative predictive values confirmed the reliability of ruling out non-metastasis when screening for metastasis. Computer-based image processing techniques demonstrated excellent diagnostic accuracy for bone metastasis in patients with lung cancer. Further studies should focus on investigating a unique standardized diagnostic tool that can be applied in a clinical setting to improve patient management.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 5","pages":"182"},"PeriodicalIF":2.2,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of induction chemotherapy combined with standard chemoradiotherapy vs. standard chemoradiotherapy monotherapy in locally advanced cervical cancer:  A systematic review and meta-analysis.","authors":"Xinyu Lu, Yaxu Su, Wentong Xu, Tianyou Tang, Fengjuan Zhou, Dehong Yu, Yilong Guo, Yong Xin","doi":"10.3892/ol.2026.15538","DOIUrl":"10.3892/ol.2026.15538","url":null,"abstract":"<p><p>Concurrent chemoradiotherapy (CCRT) is the standard treatment for locally advanced cervical cancer (LACC); however, the role of additional induction chemotherapy (IC) remains debated. The present study performed a systematic review and meta-analysis of randomized controlled trials (RCTs) to comparatively assess therapeutic outcomes and safety profiles between induction chemotherapy followed by concurrent chemoradiotherapy (IC + CCRT) versus CCRT alone in patients with locally advanced cervical cancer (LACC) (International Federation of Gynecology and Obstetrics 2018 stage IB2-IVA). The study screened relevant literature published up to March 2025 and ultimately included 6 RCTs, where 1,006 patients were stratified (504 in the IC + CCRT regimen vs. 502 in the CCRT alone regimen). Compared with CCRT alone, IC + CCRT significantly improved the complete response (CR) rate [odds ratio (OR), 1.95; 95% confidence interval (CI), 1.20-3.17; P=0.007] and 1-year progression-free survival rate (OR, 1.82; 95% CI, 1.14-2.90; P=0.01). A consistent trend favoring IC+CCRT was observed for overall survival, although this was not statistically significant. Hematological toxicities, notably thrombocytopenia (OR, 1.76; 95% CI, 1.06-2.90; P=0.03) and neutropenia (OR, 2.69; 95% CI, 1.09-6.61; P=0.03), were more frequent with IC+CCRT, while non-hematological toxicity profiles were comparable. In conclusion, the addition of modern, short-course induction chemotherapy to CCRT enhances the CR rate and 1-year progression-free survival rate in LACC, establishing a promising intensified treatment strategy.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 5","pages":"183"},"PeriodicalIF":2.2,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034106/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expression of Concern] Effect of overexpression of HOX genes on its invasive tendency in cerebral glioma.","authors":"Yun-Bao Guo, Yi-Meng Shao, Jing Chen, Song-Bai Xu, Xing-Dong Zhang, Mao-Ren Wang, Hai-Yan Liu","doi":"10.3892/ol.2026.15536","DOIUrl":"10.3892/ol.2026.15536","url":null,"abstract":"","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 5","pages":"181"},"PeriodicalIF":2.2,"publicationDate":"2026-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034545/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Administration of tirabrutinib suspension in a patient with primary central nervous system lymphoma: A case report.","authors":"Takeo Yasu, Hiroaki Ohta, Yoshito Gando, Masayuki Kobayashi","doi":"10.3892/ol.2026.15531","DOIUrl":"10.3892/ol.2026.15531","url":null,"abstract":"<p><p>Tirabrutinib, a selective inhibitor of Bruton's tyrosine kinase, is approved in Japan for the treatment of relapsed or refractory primary central nervous system lymphoma (PCNSL). Dysphagia complicates oral tablet administration in patients with PCNSL. In the present case report, the safety, efficacy and plasma concentration of tirabrutinib administered as a suspension via a nasogastric tube is evaluated, providing insights into alternative administration methods and reviewing the relevant literature. In the present case, a 68-year-old man with PCNSL achieved two complete responses following methotrexate-based therapies but subsequently relapsed. Owing to severe dysphagia, tirabrutinib was initially administered as a suspension via a nasogastric tube and orally, and later transitioned to oral tablets. Plasma tirabrutinib concentrations were comparable following administration via nasogastric tube, oral suspension and oral tablets. After initiating tirabrutinib treatment, the patient remained clinically stable, with no recurrence of lymphoma for 1 year and no adverse events observed. A literature review identified 17 studies describing 19 patients who received a tyrosine kinase inhibitor (TKI) as a suspension. Tirabrutinib remains a crucial treatment option for refractory PCNSL; however, alternative administration routes are required for patients with dysphagia. The present case demonstrated the feasibility and safety of tirabrutinib suspension administration, with plasma concentrations comparable to those achieved with tablet administration. Further pharmacokinetic studies are warranted to evaluate the administration of TKI suspensions in a broader patient population.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 5","pages":"176"},"PeriodicalIF":2.2,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Limbic encephalitis associated with anti-Hu antibody induced by atezolizumab treatment for small cell lung cancer: A case report.","authors":"Zhaohui Li, Hanping Wang","doi":"10.3892/ol.2026.15532","DOIUrl":"10.3892/ol.2026.15532","url":null,"abstract":"<p><p>With the emergence and frequent use of immune checkpoint inhibitors (ICIs), reports of immunotherapy-induced limbic encephalitis have begun to appear. The present study describes the case of a patient with small cell lung cancer who developed Hu-associated limbic encephalitis while being treated with atezolizumab. After treatment with high-dose steroids and intravenous immunoglobulin, the neurological symptoms of the patient (including confusion, short-term memory loss, disorientation, and impaired calculation ability) remained stable for 3 months, after which the patient was lost to follow-up. ICIs may accelerate autoimmune reactions that target paraneoplastic origin autoantigens. Clinicians should be alert to the risk of ICI-induced paraneoplastic neurological syndromes in patients with tumors, such as small cell lung cancer, that are traditionally associated with paraneoplastic neurological syndromes.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 5","pages":"177"},"PeriodicalIF":2.2,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing safety and efficacy in radiotherapy for external auditory canal cancer.","authors":"Yuto Imai, Taiki Takaoka, Natsuo Tomita, Mayu Kuno, Akifumi Miyakawa, Chikao Sugie, Shinya Otsuka, Kaoru Uchiyama, Dai Okazaki, Masanari Niwa, Akira Torii, Nozomi Kita, Masanosuke Oguri, Seiya Takano, Takuma Matoba, Daisuke Kawakita, Shinichi Iwasaki, Akio Hiwatashi","doi":"10.3892/ol.2026.15535","DOIUrl":"10.3892/ol.2026.15535","url":null,"abstract":"<p><p>External auditory canal cancer (EACC) is a rare and aggressive malignancy with no established standard treatment. The present study aimed to investigate the efficacy of radiotherapy (RT) for EACC. The data of 42 patients with EACC treated between January 2000 and August 2023 were retrospectively reviewed. Of these, 10 (24%) patients underwent surgery followed by RT (median dose, 60 Gy), whereas 32 (76%) underwent definitive RT (median dose, 66 Gy) and a total of 23 (72%) patients received concurrent chemotherapy with definitive RT. Overall survival (OS), local control (LC), progression-free survival (PFS) and toxicity were examined. The median age of patients was 65 years, and the median follow-up duration was 31.5 months (range: 6-120 months). In all patients, the 3-year OS, LC and PFS rates were 54.8, 65.5 and 49.0%, respectively. The 3-year OS, LC and PFS rates in patients who underwent surgery followed by RT, and those who underwent definitive RT were 90% vs. 42.9% (P=0.008), 100% vs. 53.9% (P=0.01) and 90% vs. 35.9% (P=0.003), respectively. No local recurrence occurred among those who underwent surgery followed by RT, although 50% of these patients had positive or close surgical margins. Grade ≥3 brain toxicities were observed in 3 (7.1%) patients, all of whom had T4 disease and underwent definitive RT with concurrent systemic chemotherapy. In conclusion, compared with definitive RT, surgery followed by RT was associated with favorable outcomes in patients with EACC. A multidisciplinary approach is crucial for optimizing treatment outcomes, especially for patients in the advanced stages of EACC.</p>","PeriodicalId":19503,"journal":{"name":"Oncology Letters","volume":"31 5","pages":"180"},"PeriodicalIF":2.2,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13034501/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147593586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}